Peptide Health Lab

Longevity & cellular

Epithalon

FOR RESEARCH PURPOSES ONLY

Also known as: AEDG tetrapeptide, Ala-Glu-Asp-Gly

Regulatory status
Research only
Evidence grade
Animal studies only

Last reviewed September 1, 2026 · 19 sources

What Epithalon is and how it works

Epithalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, usually abbreviated AEDG and also written Epitalon or Epithalone. It was designed in the 1980s at the St Petersburg Institute of Bioregulation and Gerontology, and the design brief is the single most important fact on this page: the sequence was chosen from the amino-acid composition of Epithalamin, a polypeptide preparation extracted from bovine pineal gland tissue.[1] The tetrapeptide is a synthetic molecule modelled on an animal-tissue extract. They are two different substances with two separate literatures, and almost every overstatement made about this compound comes from treating them as one.

The originating institute later argued that they are effectively one. Using mass spectrometry and HPLC, the group reported detecting AEDG among the tetrapeptides present in the pineal polypeptide complex, and concluded that the biological effects of the complex are determined by its AEDG component.[2] That conclusion is the hinge on which the entire read-across turns, and it is worth naming as what it is: an argument advanced by the group that developed both preparations, not an equivalence established by an outside laboratory.

The proposed mechanism is epigenetic. Short peptides of this class are said to cross the cell and nuclear membranes and interact directly with DNA and histone proteins, changing the accessibility of particular genes. For AEDG, molecular modelling placed preferential binding at histones H1/3 and H1/6, in sequences that themselves interact with DNA, and cell work reported increased expression of neurogenic differentiation genes downstream of that.[8] The best-known downstream claim is telomerase: adding the peptide to telomerase-negative human cells induced the enzyme's catalytic subunit and its activity.[3] All of that is proposed mechanism established in dishes, and mechanism is not outcome.

What the research actually shows

The tetrapeptide, in cultured human cells. This is where the evidence is deepest. In telomerase-negative human fetal fibroblasts, treatment induced telomerase catalytic-subunit expression, telomerase enzymatic activity, and telomere elongation.[3] In a follow-up, pulmonary fibroblasts that had exhausted their proliferative potential at the 34th passage went on to make ten further divisions, with telomere length restored toward early-passage values.[4] In 2025 a group at Brunel University London, outside the originating research community, reported telomere extension in normal human epithelial and fibroblast cells through hTERT and telomerase upregulation, and telomere extension in two breast cancer cell lines through alternative lengthening of telomeres instead.[5] That paper carries a published Correction, which replaced three figures without withdrawing the reported conclusions, and the corrected legends matter for how the result reads: the concentration series — 0.1 to 1 microgram per millilitre over four days — was run on the two cancer lines, while the normal fibroblast and epithelial cells each received a single concentration for three weeks. Whatever happened in the normal cells, it was not measured across a range of doses.[6]

The nearest thing to a human measurement is ex vivo. Blood lymphocytes from eleven men, five young and six middle-aged, were incubated with the peptide and assayed by fluorescence in situ hybridization. Relative telomere length changed significantly in seven individuals — up in five, by between 18% and 156%, and down in two, by 37% and 15%.[7]

The tetrapeptide, in animals. Female HER-2/neu transgenic mice treated from two months of age until death lived 13.5% longer on average and 13.9% longer at maximum, spent 34.2% longer tumor-free, and developed fewer breast adenocarcinomas.[9] A parallel experiment in the same strain reported reduced cumulative tumor number and size and a 3.7-fold reduction in HER-2/neu mRNA expression — and, importantly, that the comparator dipeptide Vilon dosed on the same schedule made the animals significantly worse.[10] In female C3H/He mice observed for 6.5 months in a study hosted at the Hebrew University of Jerusalem, with Anisimov of the originating programme as a co-author, treatment reduced the number of animals bearing malignant tumors, produced no metastases against three of nine in controls, and showed no toxic effect.[11] More recent cell work from a group at the University of Chieti-Pescara in Italy — with Khavinson and two colleagues from the St Petersburg institute among its co-authors — reported restored wound healing in a high-glucose model built from a human retinal pigment epithelial line.[12]

The extract, which is a different substance. Epithalamin — the bovine pineal preparation, not the tetrapeptide — increased mean lifespan in fruit flies, mice and rats by 11–31%, with mortality rate reduced by roughly half in flies and rats.[13] The human work everyone quotes is also the extract's. In 266 elderly persons followed for six to eight years, the originating institute and the Institute of Gerontology in Kiev reported reduced respiratory and cardiovascular morbidity and a 1.6–1.8-fold decrease in mortality in the Epithalamin arm, rising to 2.5-fold where the extract was given together with the thymic preparation Thymalin.[14] A separate 12-year study of the extract in elderly patients with coronary disease, described by its authors as randomized, reported 28% fewer deaths.[15] A third reported that a course of the extract raised night-time plasma melatonin in elderly subjects whose pineal activity was already low, while tending to lower it in those whose function was normal.[16] None of those three studies administered AEDG.

The tetrapeptide, in people. Two indexed reports exist, both from the originating institute. One states that treatment produced a positive clinical effect in 90% of patients with degenerative retinal lesions, and its abstract reports no sample size, no control group, no blinding, and no defined endpoint.[17] The other reports a 1.7-fold rise in urinary 6-sulfatoxymelatonin in middle-aged people whose excretion was low at baseline, together with normalized expression of the circadian genes Clock, Csnk1e and Cry2 in blood cells.[18] That is the whole of it.

Where the evidence is weak

The famous human result is not this compound's. The 266-person cohort, the mortality reductions, the twelve-year follow-up: every one of those belongs to Epithalamin, an extract prepared from bovine pineal tissue, and in the largest cohort the reported benefit came partly from combining it with a second preparation.[14][15] The claim that the extract's effects are attributable to its AEDG content is an argument the originating institute made about its own two products.[2] It may be right. It has not been tested by anyone else.

Human cells are not humans. Telomerase induction, telomere elongation and Hayflick-limit extension were all measured in flasks, and the ex vivo lymphocyte result moved downward in two of eleven participants.[3][4][7] No published work connects a telomere measurement in a dish to any clinical outcome in a person.

The animal lifespan result comes from cancer-prone strains. HER-2/neu mice die of mammary tumors. A treatment that suppresses those tumors will extend their lifespan without necessarily slowing aging, and the two effects cannot be separated in that design.[9]

A near-identical peptide made the same model worse. In the mammary-tumor experiment, Vilon increased cancer incidence, shortened tumor latency, and raised cumulative tumor number.[10] Whatever this class of molecules does, it is not uniformly protective, and the assumption that a short peptide is inherently gentle does not survive that comparison.

Almost the entire literature comes from one institute and its collaborators. The Brunel University London telomere paper is the only clear exception among the primary studies, and it is cell culture.[5] The two papers that look independent because of where they were run are not: the C3H/He carcinogenesis study was hosted at the Hebrew University of Jerusalem with Anisimov — first author of both HER-2/neu mouse papers cited above — on its author list, and the 2025 retinal work was run at Chieti-Pescara with Khavinson and two St Petersburg colleagues among its authors.[11][12] A host laboratory in another country is not an independent replication. Reviews written outside that community describe a compound with promising preclinical signals that has not been through the validation that would make any of it clinically meaningful, and specifically note the absence of long-term safety data.[19][1]

There is no registered, blinded, independent human trial of AEDG. Not a negative one — none at all. The two human reports on the tetrapeptide describe no control condition, and one reports no sample size. Neither can support a statement about what this molecule does to a person.[17][18]

Nothing guarantees identity. With no approved manufacturer, the sequence, concentration and contaminant profile of material carrying this name are unregulated, and the surrounding vocabulary — tetrapeptide, extract, polypeptide complex, three spellings of the same name — makes mislabeling unusually easy to miss.[1]

Legal and regulatory status

Epithalon is not approved by the FDA for any indication. A search of approved drug products under both the Epithalon and Epitalon spellings, and under the sequence designations, returns no application with this peptide as an active ingredient and no approved labeling, while a control query of the same shape in the same session returned approved biologic applications as expected. It does not appear in any category of the FDA's list of bulk drug substances nominated for use in compounding under section 503A, in which other research peptides do appear. It is not an approved drug and it is not a dietary supplement ingredient; material carrying the name is distributed for laboratory research use, which is why every mention of it on this site carries research-only framing.

Outside the United States the picture is different in kind, not in weight. The compound and the pineal extract it was modelled on originate in Russian and Ukrainian gerontology research, and short peptide bioregulator preparations of this family are marketed in Russia. PHL was not able to establish a marketing authorization for the AEDG tetrapeptide as a registered medicine in any jurisdiction, and states that as the limit of what it verified rather than as a finding either way. A preparation being marketed somewhere is not a regulatory approval, a registered medicine in one country is not an approval in another, and neither is a substitute for the review the FDA has not conducted. None of it tells a reader anything about the quality of a particular container of powder. A review that searched regulatory as well as bibliographic databases through January 2026 grouped this compound with the non-approved peptides that have preclinical support and no systematic clinical validation.[19]

PHL does not sell peptides, does not tell anyone where to obtain anything, and takes no position on how unapproved material reaches anyone. What the regulatory status means for a reader is narrower and more useful than any argument about enforcement: there is no label, no approved manufacturer, no assigned indication, and no regulated quality standard behind anything carrying this name.

Questions to bring to a provider

The useful conversation is not "should I try Epithalon." It is "here is the aging-related concern I actually have, here is what I read, and how much of what I read was about this molecule at all." Questions worth raising:

  • When a source cites the 266-person mortality study, does it say that the study used a bovine pineal extract rather than the synthetic tetrapeptide, and that the largest reported effect came from combining two preparations?[14]
  • Given that every telomere result was obtained in cultured cells, what would have to be measured in a person for any of it to mean something?[3][5]
  • With a personal or family history of malignancy, how should a compound whose signature mechanism is telomerase induction be thought about, and does the rodent finding that a related peptide worsened tumor outcomes change that conversation?[10]
  • Does anything about a reported change in a melatonin metabolite justify expecting a change in sleep, given that no study has measured one?[18]
  • Which specific, measurable thing would tell either of us whether anything happened at all, rather than relying on how it feels over a few months?[19]

A clinician who answers "the human evidence you have read about is for a different substance" is describing the literature accurately.

Evidence by claim

Grades describe how strong the evidence is; the line under each grade describes what kind of studies it is. How we grade evidence.

Telomerase activation and telomere elongation in human cells
Animal studies only in vitro

This is the compound's strongest and most reproduced result, and it is cell culture. Adding the peptide to telomerase-negative human fetal fibroblasts induced expression of the telomerase catalytic subunit, telomerase enzymatic activity, and telomere elongation. An independent group at Brunel University London reported telomere extension in normal human epithelial and fibroblast cells through hTERT and telomerase upregulation, and in two breast cancer cell lines through alternative lengthening of telomeres. Per that paper's corrected figure legends the concentration series was run on the cancer lines only; the normal cells received a single concentration for three weeks, so no dose-response was established in them. Human cells in a flask are not humans.

[3] [5] [6] [7]

Extension of the replicative lifespan of cultured human cells
Animal studies only in vitro

Primary human fetal pulmonary fibroblasts that lost proliferative potential at the 34th passage made ten further divisions after peptide treatment, with telomeres restored to a length comparable to early passages. The authors described this as overcoming the Hayflick limit. It is one experiment in one cell line from the originating institute, and a cell population that keeps dividing is not an organism that lives longer.

[4]

Lifespan and tumor development in rodents
Animal studies only animal

In female HER-2/neu transgenic mice treated from two months of age until death, the tetrapeptide extended mean lifespan by 13.5% and maximum lifespan by 13.9%, extended tumor-free lifespan by 34.2%, and reduced breast adenocarcinoma incidence. A parallel experiment reported reduced cumulative tumor number and maximum tumor size, and a 3.7-fold reduction in HER-2/neu mRNA expression. In female C3H/He mice observed for 6.5 months, treatment reduced the number of animals with malignant tumors and no metastases were found. These are cancer-prone strains, so a lifespan gain in them is entangled with tumor suppression rather than independent of it.

[9] [10] [11]

Gene expression and cell differentiation as the proposed mechanism
Animal studies only in vitro

In human gingival mesenchymal stem cells the tetrapeptide raised mRNA expression of the neurogenic differentiation markers Nestin, GAP43, beta-tubulin III and doublecortin by 1.6–1.8 times, and molecular modelling suggested preferential binding to histones H1/3 and H1/6 at DNA-interacting sites. In a high-glucose model of diabetic retinopathy built from a human retinal pigment epithelial line, the peptide restored impaired wound healing. Both are cell-level results, and the histone binding is modelled rather than measured in a cell.

[8] [12]

Reduced morbidity and mortality in older people given Epithalamin, the bovine pineal extract — not the AEDG tetrapeptide
Anecdotal reports only human observational · human RCT

This claim belongs to Epithalamin, the bovine pineal polypeptide extract, and not to the synthetic tetrapeptide. In 266 elderly persons followed 6–8 years, the originating institute and collaborators in Kiev reported reduced acute respiratory disease and cardiovascular morbidity and a 1.6–1.8-fold decrease in mortality in the Epithalamin-treated group, and a 2.5-fold decrease where the extract was combined with the thymic preparation Thymalin. A separate 12-year study of the same extract in elderly patients with coronary disease, described by its authors as randomized, reported 28% fewer deaths than control. Neither abstract describes blinding, both come from the research community that developed the preparations, and neither administered the tetrapeptide this page is about.

[14] [15]

Any clinical effect of the AEDG tetrapeptide in people
Anecdotal reports only human observational · review

Two indexed reports gave the tetrapeptide itself to people, both from the originating institute. One described a positive clinical effect in 90% of patients with degenerative retinal lesions, reporting no sample size, no control group, no blinding and no defined endpoint in its abstract. The other reported a 1.7-fold increase in urinary 6-sulfatoxymelatonin excretion in middle-aged people whose excretion was low at baseline, along with normalized expression of the circadian genes Clock, Csnk1e and Cry2 in blood cells, again without a described control condition. Those are biomarker and impression-level observations. No registered, blinded, independently conducted human trial of this tetrapeptide has been published.

[17] [18] [19]

Sleep
Anecdotal reports only human observational

No published study has measured a sleep endpoint for this tetrapeptide. The melatonin work that anchors the sleep framing was done with the bovine pineal extract, in elderly subjects, and measured plasma melatonin concentration across the day rather than sleep: concentration rose during the dark period in subjects whose pineal activity was low at baseline and tended to fall in those whose function was normal. The human circadian work on the tetrapeptide measured a urinary melatonin metabolite and gene expression, not sleep latency, duration, architecture or quality. A melatonin marker moving is not a night of sleep changing.

[16] [18]

FOR RESEARCH PURPOSES ONLY

Typical protocol range in the research

  • The two rodent carcinogenesis experiments — female HER-2/neu transgenic mice and female C3H/He mice — on intermittent schedules expressed per animal rather than per kilogram. The mammary-tumor study states subcutaneous injection; the C3H/He abstract reports only that the peptide was injected and names no route

    1 microgram per mouse for five consecutive days every month from two months of age in the mammary-tumor experiment, and 0.1 microgram five times weekly for 6.5 months in the spontaneous-carcinogenesis experiment [10] [11]

  • The separate HER-2/neu transgenic mouse lifespan experiment that produced this page's headline 13.5%, 13.9% and 34.2% figures, dosed by subcutaneous injection from the second month of life until death

    1 mg per mouse five times weekly — a thousand times the per-animal amount used in the mammary-tumor experiment from the same research programme, which is a spread the two abstracts do not explain [9]

  • Human breast cancer cell lines 21NT and BT474 in the telomere-length experiment at Brunel University London, as the corrected figure legends describe them

    0.1, 0.2, 0.5 and 1 microgram per millilitre added to the culture medium for four days, with untreated cells as the control [5] [6]

  • The normal-cell arms of the same Brunel experiment — IBR.3 fibroblasts and HMEC epithelial cells — which the corrected figure legends describe on a different schedule from the cancer lines

    A single concentration, 1 microgram per millilitre, for three weeks, with untreated cells as the control. No concentration series was run on these cells [5] [6]

  • Humans, administered the AEDG tetrapeptide, any indication

    No dose is established. The two indexed reports in which the tetrapeptide itself was given to people — a retinal-degeneration series and a circadian-marker study — describe neither the amount given nor the schedule in their published abstracts, so there is no human figure this page can report [17] [18]

Every figure above comes from an animal experiment or a cell-culture dish, and the animal figures themselves span three orders of magnitude between two studies from the same programme. A microgram injected into a mouse and a microgram per millilitre in a flask are not convertible into anything for a person, and no published work has attempted that conversion. Community-circulated human schedules have no published source behind them and therefore do not appear here.

Ranges are what published research reports, not a recommendation. PHL does not prescribe, and nothing here is personalized to you.

Side effects & safety signals

  • No characterized human safety profile for the tetrapeptide

    Not established · Unknown, and that is an absence of data rather than a finding of safety. A narrative review that searched regulatory as well as bibliographic databases through January 2026 placed Epitalon among the non-approved peptides that show preclinical and limited clinical evidence but lack long-term safety data and systematic validation.

    [19]

  • Not every short peptide is benign in the same tumor model

    Reported once, in the study's comparator arm · In the HER-2/neu transgenic mouse experiment, the comparator dipeptide Vilon (Lys-Glu) — dosed on the same schedule, from the same research programme — produced significant negative effects relative to control: increased mammary cancer incidence, a shorter mean latent period, and an increased cumulative number of tumors. Epitalon did not do that in the same experiment. The signal is a reason to treat "short peptides are gentle regulators" as a hypothesis rather than a class property, and it is a provider-discussion flag for anyone with a personal or family malignancy history.

    [10]

  • Telomerase and telomere-lengthening activity itself

    Consistently reported in cultured human cells · The mechanism the compound is best known for is the induction of telomerase activity and the elongation of telomeres in human cells in culture, and an independent laboratory reported telomere lengthening in two breast cancer cell lines through alternative lengthening of telomeres instead. Telomerase reactivation is also a feature of most human cancers, and no published work has examined what sustained telomerase induction does in a living person. That is a question to raise with a clinician, not a settled risk and not a settled non-risk.

    [3] [5]

  • Direction of effect on telomere length is not uniform

    Reported in 2 of 11 participants in the lymphocyte study · When the tetrapeptide was incubated with PHA-stimulated blood lymphocytes from eleven men, relative telomere length rose significantly in five individuals but fell significantly in two, by 37% and 15%. The authors read the pattern as a tendency toward normalization. Either way, it is not a uniform lengthening effect, and a marker that can move down as well as up is not a marker anyone can currently steer.

    [7]

  • Unverified identity and purity of unapproved material

    Not quantified · With no approved manufacturer, nothing about the sequence fidelity, concentration, or contaminant profile of material carrying this name is regulated or independently guaranteed. The problem is sharper here than for most compounds on this site, because the tetrapeptide, the bovine pineal extract it was modelled on, and a family of near-identical short peptides are all discussed under overlapping names. This is a category-level risk that sits on top of whatever the molecule itself does.

    [1] [19]

Published lists are never exhaustive, so report anything unexpected to a licensed provider.

Storage, handling & reconstitution

Lyophilized storage
Lyophilized Epithalon is conventionally kept refrigerated at 2–8 °C and protected from light, with freezing used for longer holding. The published literature on this tetrapeptide is concerned with its biological activity in cells and animals rather than with vial shelf life, and no stability study for the peptide has been published, so the handling conventions here come from general lyophilized-peptide practice rather than from data about this molecule.
Reconstituted storage
Once in solution, short peptides are conventionally refrigerated at 2–8 °C, protected from light, and treated as short-dated rather than indefinitely stable. No published study establishes a solution shelf life for Epithalon.
Reconstitution diluent
Bacteriostatic water — sterile water preserved with 0.9% benzyl alcohol — is the conventional diluent for lyophilized research peptides, including this one. Preservative-free sterile water is used where a preservative is contraindicated and is treated as single-use.
Reconstitution & handling
Conventional handling only: sanitize the stopper before piercing it, add the diluent slowly down the inside wall of the vial rather than directly onto the powder, and let the powder dissolve on its own. Swirl gently if needed; never shake. A properly prepared solution is clear, and anything cloudy, discolored, or carrying visible particulate is discarded. PHL publishes no volume or unit calculations, because those are dosing decisions and dosing decisions belong with a licensed clinician.
Handling notes
There is no FDA-approved manufacturer of this tetrapeptide, so there is no label, no assigned beyond-use date, and no lot-level stability testing behind any storage claim. Everything above is convention, not specification.

The how-to guides cover the conventions behind these fields, and what the published stability data does and does not establish: Storage, Reconstitution, Handling.

Questions for your provider

Bring this page to a licensed provider. A provider can order labs, review your medications and history, and tell you whether anything here is relevant to your situation. This page can't. Peptide Health Lab does not prescribe and does not sell peptides.

Want a structured starting point for that conversation? The Stack Builder turns your goals into a research-cited outline you can review together.

Citations

19 sources · every identifier checked against PubMed

Before you act on any of this

This page is educational only and is not medical advice. It does not diagnose, treat, or prescribe. Review it with a licensed provider before making any health decision. Peptide Health Lab does not sell peptides.

How we grade and verify evidence · Terms of Use · Privacy Policy

Open the Stack Builder